Health
Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies – News-Medical.Net
Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-ca…
Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.
According to WHO reports, the current COVID-19 (coronavirus disease 2019) pandemic has caused more…
-
Noosa News23 hours agoUnlawful wounding charges, Caloundra – Sunshine Coast
-
Business16 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
General18 hours agoFootballers and movie stars: PM’s Shanghai tourism push
-
General15 hours ago‘Hidden and radical’ power of First Nations women unlocked in big hART’s Punkaliyarra project